Drug Trial Radar · NCT07327034
ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression
Last checked: Nov 20, 2026Latest source record: Jan 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
141
Planned (sponsor's estimate)
Start
Jun 13, 2025
Primary completion
Jun 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, multicenter, Phase 2 study to evaluate the efficacy and safety of ABSK-011 plus BSC versus placebo plus BSC in advanced or unresectable hepatocellular carcinoma (HCC) patients with FGF19 overexpression who have received prior systemic therapy. Approximately 141 advanced or unresectable HCC patients with FGF19 overexpression who have received prior systemic therapy will be enrolled and randomized to experimental arm or control arm in a 2:1 ratio. Patients will receive assigned study treatment, every 28-day treatment cycle within 1 day of randomization until disease progression, intolerable toxicity, start of new anti-tumor therapy, death, patient refuse to continue treatment, loss to follow-up, or other reasons leading to treatment discontinuation. Immediate BICR review is required for patients with radiographic disease progression as assessed by the investigator. If disease progression is assessed by BICR, the investigator is allowed to unblind after disease progression according to the protocol-specified procedures. After unblinding, patients in the experimental arm, study drug should be discontinued. Patients in the control arm may be transferred to receive ABSK-011 plus BSC after assessment.
Conditions
- Hepatocellular Carcinoma (HCC)
Interventions
ABSK-011+BSCDrug
ABSK-011 capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.
Placebo+BSCDrug
Placebo capsules will be provided and should be taken twice daily, with an interval of approximately 12 hours. The investigational product should be taken with food, with approximately 150 mL of water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORR by BICRTime frame: through study completion, up to 2 years
Locations
51 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Cancer Hospital
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
The First Affiliated Hospital of USTC
Hefei, Anhui, China · Recruiting
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Beijing Tsinghua Changgung Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing university cancer hospital
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
The Second Affiliated Hospital of Guilin Medical University
Guilin, Guangxi, China · Recruiting
Liuzhou People's Hospital
Liuzhou, Guangxi, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China · Recruiting
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China · Recruiting
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Hubei Cancer Hospital
Wuhan, Hubei, China · Recruiting
Tongji Hospital
Wuhan, Hubei, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
General Hospital of Easten Theater Command
Nanjing, Jiangsu, China · Not yet recruiting
Nanjing Tianyinshan Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital with NanJing Medical University
Nanjing, Jiangsu, China · Recruiting
Nantong Tumor Hospital
Nantong, Jiangsu, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
First Affiliated Hospital of Gannan Medical University
Ganzhou, Jiangxi, China · Recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Recruiting
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Liaoning Cancer Hospital
Shenyang, Liaoning, China · Recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Affiliated Hospital ofJining Medical University
Jining, Shandong, China · Recruiting
Eastern hepatobilliary surgery hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.